Market2C-B-ButterFLY
Company Profile

2C-B-ButterFLY

2C-B-ButterFLY, also known as 2C-B-BFLY or as 2C-B-MOTH, is a serotonin receptor modulator of the phenethylamine, 2C, and FLY families. It is a conformationally-restricted derivative of the psychedelic drug 2C-B and a ring-expanded homologue of the better-known compound 2C-B-FLY.

Use and effects
The properties and effects of 2C-B-ButterFLY in humans do not appear to be known. ==Pharmacology==
Pharmacology
Pharmacodynamics 2C-B-ButterFLY has similar properties as an agonist for serotonin receptors, but with more selectivity for 5-HT2C over 5-HT2A. ==Chemistry==
Chemistry
Analogues Analogues of 2C-B-ButterFLY include 2C-B, 2C-B-FLY, 2C-B-DragonFLY, DOB-FLY, and Bromo-DragonFLY (DOB-DFLY), among others. ==History==
History
2C-B-ButterFLY was discovered by Michael S. Whiteside and Aaron Monte in 1999. ==Society and culture==
Society and culture
Legal status Canada 2C-B-ButterFLY is a controlled substance in Canada under 2C blanket-ban language. Latvia 2C-B-ButterFLY is illegal in Latvia. United States 2C-B-ButterFLY is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption. == See also ==
tickerdossier.comtickerdossier.substack.com